Royalty Pharma has agreed to buy a royalty interest in Amgen's drug for small cell lung cancer from BeOne Medicines for up to ...

BeOne Medicines (NASDAQ:ONC) is selling its royalty rights on the worldwide sales, excluding China, of Amgen’s (NASDAQ:AMGN) cancer drug Imdelltra (tarlatamab-dlle) for up to $950M to Royalty Pharma ...

Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by Amgen Royalty ...

Investors can buy low cost index fund if they want to receive the average market return. But across the board there ...

After taking a $50 million hit in a patent lawsuit targeting its leukemia med Blincyto last year, Amgen has convinced a ...

Amgen laid out $3.7 billion to get its hands on ChemoCentryx and its approved drug Tavneos in August of 2022. At the time, ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

We can see that Amgen Inc. (NASDAQ:AMGN) does use debt in its business. But the more important question is: how much risk is ...

Clinical trial tech outfit Medidata has elevated a new strategy leader from within. | Clinical trial tech outfit Medidata has elevated a new strategy leader from within. Industry veteran Lisa ...

Biotech giant Amgen Inc. said it would cut up to 2,900 employees and close facilities in Washington state and Colorado as the Thousand Oaks company moved to rein in costs and focus on new drugs.

Amgen said it has “a number of preclinical candidates” in the Alzheimer’s field. BACE inhibitors are the latest hope in the fight against Alzheimer’s, but are no sure thing.

Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for ...